Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 29 - Caught on Camera

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

StockNews.com

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Telanagana: Spurious antibiotics worth Rs 1.33 crore seized from a pharmaceutical company

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Dynamite News

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?

AMD stock faces bearish wave, below key moving averages with neutral RSI. Short-term rebound possible, but overall technicals and market share gains uncertain.

Benzinga

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Milestone Scientific Secures Federal Supply Schedule Approval On Contract For CompuFlo Epidural System

Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced its approval on contract for the Federal Supply Schedule

Benzinga

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Benzinga

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Benzinga

AIM ImmunoTech Issues Presentation Detailing Case For Re-Electing Current Directors To Oversee Continued Momentum And Drive Strategy To Create Long-Term Value For Patients And Shareholders; Warns Shareholders Of Its Belief That The Activist Group And Its Nominees Have A Self-Interested Agenda And Could Put AIM's Clinical Progress At Risk

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commercialization Opportunities in High-Value Indications Including Pancreatic CancerWarns Shareholders

Benzinga

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts

Rhythm Pharmaceuticals (NASDAQ:RYTM) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

I love the ingenious design of this women’s health brand logo

Design Bridge and Partners create a pioneering brand for the future.

Creative Bloq

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Democrats can still lower drug prices

High medication costs are a common enemy for Democrats, Republicans and patients. There's still time to fight

International Business Times

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

Top News

FDA Implements New Rules For Drug Advertisements

New FDA guidelines enhance transparency in TV drug ads by requiring clearer risk information and neutral presentation of side effects.

The Independent UK

New FDA rules for TV drug ads: Simpler language and no distractions

New rules require drugmakers to be clearer about explaining the risks and side effects of prescription drugs

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

23andMe is laying off 40% of its workforce right before the holiday season

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach, several rounds of previous layoffs and piling losses that plunged the company’s stock over recent years

The Guardian - UK

AstraZeneca’s numbers are good but trouble in China could drag it down

Profits beat forecasts but a 17% fall in share price since executives were detained by Beijing may be hard to shake

The Independent UK

23andMe cuts 40% of its workforce and discontinues therapeutics division

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs

The Guardian - UK

AstraZeneca says it takes China investigation ‘very seriously’

UK’s biggest pharmaceutical company ‘committed to China’ as it raises 2024 profit forecast and announces $3.5bn US investment

USA Today Sports Media Group

All that You Really want to Be familiar with Arimidex

Arimidex (Anastrozole) is a major area of strength for an inhibitor reliably used to direct estrogen levels in both sensible and lifting loads settings. At first expected to oversee chest most harmful developments in postmenopausal women, Arimidex ...

International Business Times

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

The Guardian - UK

AstraZeneca shares tumble after reports China unit is linked to insurance fraud

Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price

1 … 28 29 30 31

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Gilead Sciences

118 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.